Causes of rare forms eye disorders in young patients discovered

Article

Through the use of next-generation DNA sequencing techniques, researchers from the University of Leeds have discovered the causes of rare forms of inherited eye disorders in paediatric patients.

Through the use of next-generation DNA sequencing techniques, researchers from the University of Leeds have discovered the causes of rare forms of inherited eye disorders in paediatric patients.

In collaborative work with colleagues at Flinders University in Adelaide, Australia, Dr Manir Ali and team (University of Leeds, UK) studied the DNA from three unrelated families that all had members with a history of poor vision from birth linked to the eye's lens and cornea. It was found that all the family members with impaired vision had defects in an antioxidant protein, peroxidasin, which assists in the development of lens and cornea.

The technique used to make the discovery, next-generation DNA sequencing, allows genes to be read quickly and enables users to spot errors that cause inherited disorders. It is hoped that this discovery will help in the identification of families at risk of conceiving children with severe vision impairment, so that appropriate counselling can be given. Additionally, further worked is planned to use the same technique in screening every eye gene simultaneously to assist in diagnosis and treatment time.

Full details of the study were published in the American Journal of Human Genetics and more information may be found on the University's website: www.leeds.ac.uk

Recent Videos
Dr Rick Lewis discusses the FLigHT procedure and ViaLase laser at the 2024 European Society of Cataract and Refractive Surgeons (ESCRS) meeting
Christiana Dinah speaks about her ASRS presentation, Real-World Treatment Outcomes With Anti-VEGF Therapy in Patients With Retinal Vein Occlusion in the UK
Chase Ludwig, MD, shared an overview of his presentation, which covered real-impact of vitrectomy surgery on the progression of AMD at the annual ASRS meeting in Stockholm, Sweden
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.